Related Experiment Video
Updated: Oct 21, 2025

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy
Published on: December 16, 2021
RNA Methylations in Cardiovascular Diseases, Molecular Structure, Biological Functions and Regulatory Roles in
Wanwan Zhou1, Changhui Wang2, Jun Chang3
1Department of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China.
Insights
RNA methylations, including m6A, are crucial in cardiovascular diseases (CVDs). Understanding these RNA modifications offers new diagnostic and therapeutic targets for heart conditions.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiology
Background:
- Cardiovascular diseases (CVDs) remain a leading global cause of death.
- Current diagnostic and therapeutic strategies for CVDs require enhancement.
- RNA modifications, particularly methylation, play vital roles in cellular processes.
Purpose of the Study:
- To review the molecular structures and biological functions of five RNA methylations: m6A, m5C, m1a, m6am, and m7G.
- To examine the effects of these RNA methylations on various cardiovascular diseases.
- To highlight RNA methylation as a potential area for novel CVD biomarkers and therapies.
Main Methods:
- Literature review focusing on the roles of RNA methylations in CVD pathogenesis.
- Analysis of the mechanisms involving RNA methylation 'writers', 'erasers', and 'readers'.
- Synthesis of current knowledge on m6A, m5C, m1a, m6am, and m7G in cardiovascular conditions.
Main Results:
- RNA methylations significantly impact RNA processing, including nuclear export, translation, and splicing.
- The m6A modification, regulated by writers, erasers, and readers, influences mRNA fate in CVDs.
- Emerging roles of m5C, m1a, m6am, and m7G in CVDs warrant further investigation.
Conclusions:
- RNA methylations are increasingly recognized as critical players in cardiovascular pathophysiology.
- Further research into RNA methylation mechanisms can uncover new diagnostic markers for CVDs.
- Targeting RNA methylation pathways presents a promising avenue for developing innovative therapeutic strategies for cardiovascular diseases.
Abstract:
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality in the world. Despite considerable progress in the diagnosis, treatment and prognosis of CVDs, new diagnostic biomarkers and new therapeutic measures are urgently needed to reduce the mortality of CVDs and improve the therapeutic effect. RNA methylations regulate almost all aspects of RNA processing, such as RNA nuclear export, translation, splicing and non-coding RNA processing. In view of the importance of RNA methylations in the pathogenesis of diseases, this work reviews the molecular structures, biological functions of five kinds of RNA methylations (m6A, m5C, m1a, m6am and m7G) and their effects on CVDs, including pulmonary hypertension, hypertension, vascular calcification, cardiac hypertrophy, heart failure. In CVDs, m6A "writers" catalyze the installation of m6A on RNAs, while "erasers" remove these modifications. Finally, the "readers" of m6A further influence the mRNA splicing, nuclear export, translation and degradation. M5C, m1A, m6Am and m7G are new types of RNA methylations, their roles in CVDs need to be further explored. RNA methylations have become a new research hotspot and the roles in CVDs is gradually emerging, the review of the molecular characteristics, biological functions and effects of RNA methylation on CVDs will contribute to the elucidation of the pathological mechanisms of CVDs and the discovery of new diagnostic markers and therapeutic targets of CVDs.
Related Concept Videos
Biosynthesis of Nucleic Acids
Epigenetic Regulation
X-chromosome...
RNA Stability
Nuclear Export of mRNA
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...

